When was AnchorDx founded?

AnchorDx was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is AnchorDx located?

AnchorDx is headquartered in Guangzhou, China.

How many employees does AnchorDx have?

As of Sep 30, 2026, the latest employee count at AnchorDx is 16.

Is AnchorDx a funded company?

AnchorDx is a funded company, having raised a total of $73M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 01, 2015.

When was the latest funding round of AnchorDx?

AnchorDx's latest funding was a $***** Series C round on Feb 22, 2021, with participation from 1 investor.

Where does AnchorDx rank among its competitors?

AnchorDx ranks 7th amongst 77 active competitors, of which 18 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Genome Medical, which secured $75.3M in Sep, 2024.

Who are the top competitors of AnchorDx?

AnchorDx's top competitors include Fulgent Genetics, Myriad Genetics and Invitae. Among them, Genome Medical secured the most recent funding round in September, 2024.

AnchorDx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of high throughput gene sequencing platform for clinical application. It enables early diagnosis of genetic diseases and thereby intervene and reduce the incidence of the disease. Its proprietary test menu includes non-invasive prenatal testing, pre-implantation carrier screening, cancer diagnostics, and liquid biopsy tests.

Key Metrics

Founded Year

2015

Location

Guangzhou, China

Stage

Series C

Total Funding

$73M in 3 rounds

Latest Funding Round

Series C, Feb 22, 2021, $*****

Investors

Orbimed & 6 more

Ranked

7^th among 77 active competitors

Employee Count

16 as on Sep 30, 2026

Similar Companies

OpenEvidence & 2974 more

View AnchorDx's full profile

AnchorDx has raised a total funding of $73M over 3 rounds. Its first funding round was on Dec 01, 2015. Its latest funding round was a Series C round on Feb 22, 2021 for $*****. 1 investor participated in its latest round. AnchorDx has 7 institutional investors.

Here is the list of recent funding rounds of AnchorDx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 22, 2021	3511192	Series C	8407615	6394912	6477981	9576999
Nov 07, 2017	8120254	Series B	7051973	6827983	9859839	Arch Venture Partners & 2 more
Dec 01, 2015	5650426	Series A	1771429	5521103	5957178	NLVC

Access funding benchmarks and valuations. Sign up today!

View details of AnchorDx's funding rounds and investors

The founders of AnchorDx is Fan Jianbing.

Here are the details of AnchorDx's key team members:

Fan Jianbing: Founder & CEO of AnchorDx.
Contact Info: 1 email address

View details of AnchorDx's Founder profiles and Board Members

AnchorDx's employee count trend

AnchorDx has 16 employees as of Sep 26. Here is AnchorDx's employee count trend over the years:

Uncover AnchorDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AnchorDx include Fulgent Genetics, Myriad Genetics and Invitae. Here is the list of Top 10 competitors of AnchorDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Fulgent Genetics 2011, Temple City (United States), Acquired	Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer	$34.8M	-	70/100
2nd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	66/100
3rd	Invitae 2010, San Francisco (United States), Public	Provider of home-based genetic test for individuals	$190M	Perceptive Advisors, Rock Springs Capital ... & 22 others	64/100
4th	Celmatix 2009, New York City (United States), Series C	Pioneering ovarian health therapeutics for women's unique biological needs	$24.9M	Topspin Consumer Partners, Partnership for New York City ... & 4 others	56/100
5th	Genome Medical 2016, Monterey (United States), Series D	Provider of clinical and DTC genomic testing services	$173M	Samsung Catalyst Fund, Canaan & 21 others	54/100
6th	Centogene 2006, Rostock (Germany), Public	Provider of biochemical/genetic tests to detect mutations and rare diseases	$28M	TVM Capital, Deutsche Private Equity & 2 others	50/100
7th	AnchorDx 2015, Guangzhou (China), Series C	Developer of high throughput gene sequencing platform for clinical application	$73M	Arch Venture Partners, NLVC & 5 others	48/100
8th	Blueprint Genetics 2012, Espoo (Finland), Acquired	Provider of genetic diagnostics and clinical interpretation for hereditary diseases	$26.2M	Inventure, MTIP & 4 others	48/100
9th	Recombine 2011, New York City (United States), Acquired	Genetic testing services	$12.1M	FirstMark, Vast Ventures & 3 others	48/100
10th	Mira Dx 2008, New Haven (United States), Series A	miRNA-based diagnostic tests	$7.16M	Connecticut Innovations, Westway Capital	47/100